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Abstract
Engineering the entire genome of an organism enables large-scale changes in organization, function,
and external interactions, with significant implications for industry, medicine, and the environment.
Improvements to DNA synthesis and organism engineering are already enabling substantial changes to
organisms with megabase genomes, such as Escherichia coli and Saccharomyces cerevisiae. Simulta-
neously, recent advances in genome-scale modeling are increasingly informing the design of metabolic
networks. However, major challenges remain for integrating these and other relevant technologies into
workflows that can scale to the engineering of gigabase genomes.
In particular, we find that a major under-recognized challenge is coordinating the flow of models,
designs, constructs, and measurements across the large teams and complex technological systems that
will likely be required for gigabase genome engineering. We recommend that the community address
these challenges by 1) adopting and extending existing standards and technologies for representing and
exchanging information at the gigabase genomic scale, 2) developing new technologies to address major
open questions around data curation and quality control, 3) conducting fundamental research on the
integration of modeling and design at the genomic scale, and 4) developing new legal and contractual
infrastructure to better enable collaboration across multiple institutions.
1 From Engineering Genes to Engineering Genomes
Engineering the entire genome of an organism will allow large-scale changes in organization, function, and
environmental interactions, with major implications for applications of biotechnology broadly [1]. The past
several decades have seen remarkable progress in our capability to create DNA and modify genomes [2–4].
Since Khorana created the first synthetic gene forty years ago [5], our capability to construct DNA sequences
has doubled approximately every three years (Figure 1A), progressing from plasmids in the early 1990’s [6,
7], viruses in the early 2000’s [8], and gene clusters in the mid-2000’s [9, 10], to the first bacterial chromosome
in 2008 [11, 12]. More recently, several groups have demonstrated the feasibility of total synthesis of the
4 Mb genomes of Escherichia coli [13, 14] and Salmonella typhimurium [15], and the Sc 2.0 project [16,
17] has nearly completed re-engineering the 11.4 Mb genome of Saccharomyces cerevesiae [18]. Projecting
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Figure 1. As capabilities for genome engineering advance rapidly, the size of teams involved in each genome engineering
project also increase. (a) From 1980 to present, the size of the largest engineered genomes has grown exponentially, doubling
approximately every three years. Extrapolating this trend projects gigabase engineering becoming feasible by 2050. (b) The
sizes of the teams needed to produce these genomes has also grown exponentially, scaling with the cube root of genome size
and suggesting that teams on the order of 500 investigators will be needed to engineer gigabase genomes. Data for this figure
is provided in Supplementary Data 1.
further to the gigabase scale, in 2016 leaders from academia and industry formed the Genome Project-
Write [1] consortium to roadmap new technical approaches and ethical frameworks for engineering the
genomes of higher-order organisms. Since then, members of the consortium have proposed projects to develop
human cell lines with engineered genomes, including a virus-resistant, ultra-safe cell line for pharmaceutical
production [19].
Moving to the gigabase scale poses major technological and scientific challenges, with scaling up DNA
synthesis and/or editing arguably foremost among these. These challenges related to synthesis and editing
have been discussed extensively, including a recent summary in [20]. However, the challenges of managing the
complex workflows and large teams needed for genome engineering not previously been analyzed. Figure 1B
shows that the number of investigators needed to engineer a genome has also risen markedly with the size of
the genome. If both of these trends continue, then the capability to engineer gigabase eukaryotic genomes
would be projected to be realized in approximately 2050, with each such genome required a team of around
500 investigators. Thus, engineering gigabase genomes will likely require new approaches to coordinate
complex workflows and large, interdisciplinary teams.
Accordingly, we have examined the emerging design-build-test-learn workflow for genome engineering and
identified potential bottlenecks and associated solutions, as well as areas where additional research will likely
be needed. In Section 2, we discuss the emerging, design-build-test-learn workflow for organism engineering
and identify key points to integrate workflow steps across processes and/or organizations. We then discuss
each integration point in detail in Section 3, identifying gaps that must be addressed to support gigabase
engineering. Finally, in Section 4, we summarize and recommend priorities to advance genome engineering.
2 Toward Workflows for Gigabase Engineering
Gigabase engineering will likely require large-scale integration of efforts for the division, distribution, and
coordination of labor and materials. Both genome engineering and smaller-scale organism engineering work-
flows have often been abstracted and organized in terms of design-build-test-learn cycles [3, 18, 21–26]. This
iterative approach is helpful given the complexity and uncertainties in engineering biology, progressing in
incremental steps, implementing genetic modifications in stages, and adjusting designs based on information
learned from testing prototypes and partial implementations.
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Figure 2. The emerging design-build-test-learn workflow for genome engineering is shown schematically with current (solid
arrows) and predicted (transparent arrows) tasks, interfaces (circles), and digital (white cylinders) and physical (black cylinders)
repositories.
Figure 2 shows the emerging design-build-test-learn workflow for genome engineering. The first step
in this workflow is to design a target sequence using models and design heuristics. The second step is to
build these sequences, producing and expressing DNA constructs. In the third step, the molecular and
phenotypic characteristics and consequences of these sequences are tested. Finally, researchers and engineers
improve models, design heuristics, and processes by learning from the data generated by testing, focusing
on discrepancies between the predicted and observed results.
The primary loop in Figure 2 indicates the workflow necessary for current genome engineering projects,
which have largely focused on “top-down” approaches to recode and refactor genomes, such as reducing
genomes to essential sequences. As genome writing technology matures, the focus of genome engineering
workflows may shift to more fully include the tasks in the outer loop of Figure 2. For example, one ultimate
aim of synthetic biology is to design novel genomes that encode new phenotypes from the “bottom-up” by
assembling organisms from modular parts [27]. Parts-based synthetic biology is already being used to engineer
novel metabolic pathways for commercial production of high-value chemical products, but engineering on the
genomic scale will be staggeringly more complex. In this case, sharing and reusing intermediate, mid-scale
DNA constructs that constitute biological parts and devices, as well as large-scale DNA constructs more
akin to synthetic chromosomes, will likely become increasingly important.
At each stage of the workflow, reagents, biological materials, and/or information must be transferred
through an interface from one set of processes to another, often run by investigators with complementary
areas of expertise and located in different groups or institutions. These products are both physical and
digital in nature. For example, design steps should produce sequences described in a digital format, such as
the Synthetic Biology Open Langauge (SBOL) [28, 29], which then serves as an input for experimentalists to
build those sequences. Build steps produce DNA constructs and cell lines to be tested. Test steps produce
data to be learned from. Learn steps produce data-driven and mechanistic models, ideally expressed in a
digital format. Materials and data at all stages may also reside in sample and data repositories. Genome
engineers will need interfaces to these repositories to efficiently browse, access, alter, and transfer materials,
as well as to cross-reference information across the stages of a given workflow.
Beyond the technical challenges for each stage of the workflow, genome engineering must also contend with
a number of cross-cutting issues to facilitate close coordination across many organizations. When technical
information or materials are transferred, their recipients will need to know the associated contractual and
legal obligations, such as information about intellectual property and licensing, safety, and any privacy or
personally identifiable information (PII) concerns. Additionally, issues of cybersecurity, biosecurity, and/or
biosafety may pertain at each interface.
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For gigabase engineering, every one of the interfaces between tasks, repositories, and organizations will
need to be optimized to mitigate bottlenecks to progress. For projects of this scale, ad hoc, human-centric,
and bespoke interfaces will be impractical. Instead, every interface will require representations conducive
to machine reasoning and automation, and appropriate accompanying cyber-infrastructure and tooling.
Fortunately, most of the design-build-test-learn workflow is not unique to gigabase engineering, such that
prior work in smaller-scale organism engineering provides a solid basis for paths forward from the state of
the art towards realizing effective and routine engineering of large genomes.
3 Identifying And Closing Gaps At The State Of The Art
In this section, we discuss the integration challenges identified in the previous section, reviewing the state
of the art in technologies and standards with respect to the emerging needs of gigabase genome engineering.
Instead of focusing on specific evolving protocols and methods, which are likely to advance rapidly, we
consider the information that must be communicated to enable protocols or methods to be composed into a
comprehensive workflow. Through this analysis, we identify critical gaps and opportunities, where additional
technologies and standards would facilitate workflows that are able to effectively deliver gigabase engineered
genomes. Table 1 summarizes these recommendations.
Stage Interface between workflow stages Recommendation
Design Genomic Design → Plan Assembly Extend: GFF3 and/or SBOL with chromosomal coordinates 
Design Import materials from public repositories (e.g., NCBI) Extend: existing FASTA/GenBank importers/API 
Design Sharing of genome-scale designs Adopt: SynBioHub / ICE 
Design Models → Design Cell Research: integrated CAD across multi-model repositories
Design Cell Design → Composition of Genetic Parts Research: comprehensive cell systems simulation for design evaluation
Build Assembly Plan → Synthesize Adopt: FASTA/GenBank, migrating to SBOL (function & plan for manufacturability flexibility) 
Adopt: SBOL
Extend: FASTQ, GVF, and/or SBOL with quality metric requirements 
Build Long dsDNA samples → Modify/Deliver/Integrate Extend: SBOL and/or GFF3 with integration context, modifications (e.g., BpForms) 
Build Sharing inventory of ssNA/dsNA samples, cell strains Adopt: SBOL 2.2 Design/Build/Test, ICE
Build/Test Sharing of biological samples (NAs & cells) Develop: inventory-compatible legal/contractual framework 
Test Strains → Sequence Validation Extend: FASTQ, GVF, and/or SBOL with quality metric requirements 
Develop: fitness metrics and associated specification language
Research: integrate omics and other measurements with specifications of 
desired phenotype
Test Cross-laboratory experimental data comparison Extend: process control and calibration standards 
Learn Sharing of experimental data Adopt: FAIRDOMHub, EDD or other open cloud solution 
Learn Experimental Data → Analysis Pipelines Extend: SBOL Design/Build/Test + OBO & EFO ontologies, new metadata and knowledge curation tools
Learn Analyzed Data → Create Model Research: automated and scalable model generation and verification
Extend: SBML, CellML, BioModels, and related COMBINE standards 
Research: standards for describing multi-scale modeling
Recommendation 
Adopt: CWL, container tools, PROV-O
Develop: Interoperable laboratory automation languages
Adopt: existing open DBMS solutions 
Extend: PROV-O, SBOL 2.2 Design/Build/Test 
Develop: based on OpenMTA, OSI / CC / ScienceCommons, PROV-O
Develop: based on cross-domain information sharing protocols, PROV-O
Cross-Cutting Issues
Test
Workflow Management
Learn
Short ssDNA/dsDNA Samples → AssembleBuild
Strains → Phenotype assays
Model sharing and composition 
Database federation 
Link designs → samples → strains → data → models 
IP tracking and composition 
Privacy management, public release timing 
Table 1. We assess the state of the art of gigabase-scale genome engineering. Recommendations are categorized into adopting
or extending existing technologies for near-term solutions, developing new technologies for mid-term solutions, and the need
for additional fundamental research for longer-term solutions. Color indicates technology readiness level: green indicates needs
that can be fulfilled by adopting or extending relatively mature existing methods, yellow indicates potential solutions from
extensions of the state of the art, and red indicates areas where more fundamental research is required.
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3.1 Rationally refactoring and designing gigabase genomes
The first step of the design-build-test-learn workflow is to design a synthetic genome. Currently, most
synthetic genomes are designed ad hoc using a combination of biological knowledge, engineering intuition,
and informal design heuristics. This approach has enabled projects, such as reducing Mycoplasma genomes
by eliminating non-essential elements [26], reordering genes into functional groups [17], and inserting small
metabolic pathways [30]. However, this approach can be inefficient, slow, and expensive. In contrast,
most other engineering fields, such as aerospace engineering, use computer-aided design (CAD) powered by
mechanistic models to reliably design complex systems, such as commercial jets and spacecraft. Ultimately,
CAD powered by predictive models will likely be needed to reliably design novel genomes that encode novel
functions [31]. In turn, this will require comprehensive and detailed models that can help design of entire
genomes. Substantial fundamental research is required to enable such model-driven design at the genome
scale.
As genomes cannot currently be designed de novo, for the foreseeable future, genome design will likely
involve modifying the sequences of existing organisms. Annotated genome sequences are available for diverse
organisms. Public archives, such as the National Center for Biotechnology Information, the EMBL European
Bioinformatics Institute, and the DNA Data Bank of Japan, which collectively constitute the International
Nucleotide Sequence Database Collaboration (INSDC) [32], presently contain on the order of 105 bacterial
genomes and hundreds of eukaryotic genomes [33–37].
Genome design and debugging can be further facilitated by supplementing genome sequences with addi-
tional functional annotations. For example, INSDC reference genomes primarily annotate all known tran-
scriptionally active parts of the genome, but the engineer will also need to consider tissue-specific expression
patterns. Other important sequence features include intergenic elements, including regulatory elements,
such as enhancers and silencers, structural elements, replication origins, and clinically-significant sites of
DNA recombination and instability. Much of this knowledge that can help the engineer is unfortunately dis-
tributed among many independent resources. Services such as NCBI Genome Viewer [38], WebGestalt [39]
and DAVID [40] provide programmatic or web interfaces for integrating annotations. An ideal platform for
genome design would integrate such resources with sequence editing and design tools.
The quality of annotations on a genome is another key consideration in the design process. Genomes
can have significant differences in annotations depending on the toolchains that generate them, and these
differences will likely result in trade-offs impacting engineering decisions. For example, the human reference
genomes generated by the RefSeq and GENCODE projects have notable differences [41, 42]. GENCODE
annotations have been shown to cover more coding regions and alternative splice regions and consequently
are more likely to flag a loss-of-function when a sequence variant occurs [41]. The sensitivity and specificity of
annotation tools are thus important factors in sequence design and debugging. A genome engineering effort
would therefore benefit from adoption of a standard convention for labeling annotations with estimates of
confidence and reliability, such as the RefSeq database does with the Evidence and Conclusion Ontology [43].
Collaborative design of genomes design at large scale will require an appropriate choice of data formats
and schema. Many commonly used sequence formats, such as GenBank and EMBL, are formatted for human
readability, but have significant limitations with respect to managing large genomic designs. Transferring ge-
nomic data over a network in these formats can be a significant bottleneck, due to their monolithic treatment
of sequences. Moreover, these formats are not easy to merge or harmonize across multiple concurrent users.
Fixed formats like GenBank and GFF do not facilitate integration of annotations from diverse resources,
while open semantic formats, such as SBOL, more easily support such extensions.
For communicating a genomic design, however, there are already two good options to adopt and extend.
One is the Generic Feature Format Version 3 (GFF), which allows hierarchical organization of sequence
descriptions (e.g., genes may organized into clusters, and clusters into chromosomes) and makes use of the
Sequence Ontology [44] for coherent sequence annotations. GFF has already been used in the Sc 2.0 genome
engineering project [18]. The other is the Synthetic Biology Open Language (SBOL) [45]. Like GFF, SBOL
supports hierarchical description with standardized vocabularies. SBOL, however, also allows representation
of abstract architectures in which sequences are not yet fully specified (e.g., asserting that a certain set of
genes will be used, but not yet the particular variants or their arrangement), which is useful both for in-
terchange during the design process and also for representing sequence variants and combinatorial libraries.
SBOL can also describe other molecular components and interactions in a cell (e.g., proteins, metabolites,
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regulatory interactions), allowing specification of phenotype and its linkage to genotype. This also allows
designs to be organized in terms of functional relations (e.g., metabolic pathways, cellular systems), rather
than simply genomic proximity. Finally, the SBOL standard is interoperable with SBML, allowing bidirec-
tional conversion between designs and simulation-ready models. For both GFF and SBOL, however, it would
be useful to have a richer language for specifying the position of sequences in a chromosome: the current
practice of using sequence index is fragile to unrelated distant changes impacting the alignment of design
fragments.
To date, genome engineering projects have minimally leveraged tooling that integrates sequence-design
and network-scale modeling. Models will become increasingly important as the target genomes increase
in scale or diverge from native architecture. For example, models could help predict growth phenotypes,
including non-viable states, that may result from engineering sequence elements. Network-scale models, such
as genome-scale metabolic models [46, 47] and whole-cell models [48], can be constructed by cross-referencing
annotations across multiple databases to identify gene-protein-reaction (GPR) associations. Resources, such
as the Integrated Microbial Genomes database’ [49] and the SEED [50], maintain annotated genomes that
enable automated generation of such models. Ultimately, more ambitious genome engineering projects, which
move beyond refactoring and recoding into more complex changes of organism function, will likely need to
make modeling a critical portion of the design process and will need to implement function not just at the
sequence level but by composing separately characterized genetic parts and devices. Much fundamental
research still needs to be conducted, however, before such approaches will become practical at the gigabase
genomic scale.
Additional constraints on design come from the methods used to modify genomes. This necessitates
adoption of consistent policies to resolve design conflicts, as well as to achieve the desired design objectives.
Examples of design policies include the removal of elements, such as restriction sites, separation of over-
lapping features, replacement of codons, or optimization of nucleotide content for synthesis. In the Sc 2.0
project, design policies were semi-formalized through group consensus, but in practice were implemented by
a combination of customized software tools or manual sequence editing. Such policies could be enhanced
by encoding synthesis expertise in the form of rules-based ontologies [51, 52]. The BOOST tool developed
by JGI provides a prototype for such a language [53]. Synthesis providers could also use such methods to
encode their synthesis constraints, enabling automatic pre-qualification of designs as readily compatible with
a providers’ synthesis constraints.
The business interfaces of DNA synthesis providers could also improve. Current tools typically operate
at the level of individual fragments, often ordered by a human-centric web interface or, less frequently, APIs,
with ad hoc sequence redesign based on feedback from the tool on synthesis constraints. This makes it
difficult for the designer to asses the overall impact of synthesis provider interactions in the context of the
larger design, meaning that changes made to optimizing synthesis can inadvertently disrupt vital regulatory
regions or sequences required for subsequent assembly, cloning, or sequence verification. Particular sequence
features, such as repeats, secondary structure, and high GC content, can cause synthesis failures or problems
assembling a DNA construct, often resulting in need for substantial redesign, project delays, and escalating
costs. DNA synthesis providers may also have constraints specific to their platforms. Large-scale construction
would be better supported by more standardized interfaces that would allow designers and synthesis providers
to share a complete construct design in a common data format, including genomic context, annotation
with desired functional biological features, and assembly plans (e.g., Gibson junctions). This would then
allow a more collaborative interaction, in which the synthesis service can optimize for synthesis, or at least
recommend solutions to the user, while remaining within the constraints of the original design and tracking
the relation between suggested changes and the original target sequence. This also has an additional benefit
for biosecurity, as the intent behind synthesis orders becomes more transparent. The SBOL format is well-
suited for supporting such annotations, though GenBank and GFF could also potentially be extended to
encode this information.
3.2 Building Engineered Genomes
Technology and protocols to build engineered genomes specified in the design process are advancing rapidly.
Still, the current approach of assembling DNA from smaller pieces is likely to hold for the foreseeable future
up to the gigabase scale. Building a gigabase genome will likely require synthesizing shorter DNA sequences,
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assembling these into larger constructs, and realizing the final genome that passes to the testing portion of
the engineering workflow. Discussion of scalable protocols for building gigabase-scale genomes may be found
in [1] and [20]; here, we focus on the integration challenges of workflows with such protocols.
Depending on the specific host and intended function of the engineered organism, there are typically
numerous alternative approaches and protocols for DNA synthesis, assembly, and delivery. These must
result not only in the designed DNA sequence; synthesis, assembly, and delivery must proceed in a context
that is ultimately compatible with and results in the stable expression of that genome within the host
organism with the desired phenotype. This is no small task. Currently, there is an unmet need for guidance
on best-practices for measuring, tracking, and sharing information regarding the engineered genome, as it is
built step-by-step.
Building an engineered genome, then, involves manipulating DNA many times, which offers ample op-
portunities for reduced yield, breakage, error, and other sources of uncertainty in achieving the designed
DNA sequence. Most DNA synthesis begins with shorter DNA fragments ordered from a service provider.
Biases and other sources of uncertainty in the delivered sequence associated with a synthesis platform and
method are not typically communicated in a useful fashion along with the delivered product. Rather, the
DNA is often accompanied by a certificate asserting sequence verification. Sequencing by the recipient at
this early step to verify and validate the received DNA is typically not done, due to cost and time con-
straints. However, the synthesized DNA may occasionally behave in biomolecular reactions in ways that
are unexpected based on the requested sequence, such as during polymerase chain reactions with specific
primers during amplification. This can be due to the presence of a secondary population of DNA with a
slightly different sequence, which may not be apparent from sequencing (e.g., appearing as a second band
after amplification in a gel electrophoresis separation). Large-scale operations should develop more compre-
hensive and quantitative approaches to measuring, tracking, and communicating information pertaining to
quality control.
Protocols and commercial kits to assemble shorter DNA fragments into larger constructs often involve
amplification, handling, purification, transformation, or other storage and delivery steps that can increase
uncertainty regarding the quality and quantity of the DNA. Cell-based workflows may then incorporate
growth and selection of colonies of cells that express the target constructs, thereby rejecting non-functional
or unassembled DNA sequences that may have passed through the workflow up to this point. Still, depending
on the approach, the resulting assembled DNA may include added sequences that are not biologically active,
as in the case for some methods using restriction enzymes, or scars, such as occur may occur with Golden
Gate Assembly [54] or MoClo [55]. Gibson Assembly [56] is scarless, but the yield and specific results may
depend on the secondary structure of the DNA fragments. Thus, information to track through the workflow
should include the assembly method, sequences required for assembly, and their location along the DNA
molecule, such as landing pads, sequences for compatibility with “helper” strains (typically E. coli or yeast)
used during construction, and DNA secondary structure. Larger DNA constructs are likely to be assembled
using cell-based methods such as homologous recombination in yeast [57], and cell-based platforms that
support eventual delivery to a variety of final host organisms and cell types would be desirable. Regardless
of the specific approach, however, assembly must proceed in a context that supports the packaging, delivery,
and eventual expression of the DNA in the target host, which may include imbuing the DNA with the correct
epigenetic modifications for expression to achieve the desired phenotype.
All this information must be expressed in the inputs provided from the design stage, and while FASTA
or GenBank may be sufficient for a simple sequence, more sophisticated representations, such as GFF or
SBOL [29], are needed for hierarchical construction. SBOL can also convey functional information, allowing
more manufacturing flexibility in the precise sequence chosen for construction, as well as full details of
assembly plans and records [45], such as JGI manages with its BOOST software [53]. Sequence modifications
may be expressed in an enhanced sequence encoding language, such as BpForms [58]. Sample inventories of
partially assemblies maintained as in vitro constructs or within strains may be exchanged with databases
already designed and used for such purposes, such as ICE [59] and SynBioHub [60].
The sequence of the assembled DNA is not typically verified at intermediate steps in the build process.
However, good practice dictates that the DNA should be further cloned into a cell of interest, and colonies
picked, sometimes at random, and the DNA sequenced to ensure assembly according to the intended de-
sign. Rather than sequence the entire DNA assembly, often only the specific region of interest is verified.
Throughout the DNA assembly process, an abstracted description of the process would allow for machine
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reasoning over the combination of assembly methods and verifications to achieve scale. Sequence verification
results are typically produced in FASTQ, which is generally sufficient for smaller constructs. To operate on
large-scale genomes, however, it may be important to assemble the information into more comprehensive
descriptions of a genome and its variations using representations such as GVF [61] or SBOL.
Suitable options for the delivery of large, assembled DNA constructs and whole genomes are generally
lacking. The yield of existing processes, such as electrical and chemical transformation or genome transplan-
tation, could be improved significantly to increase their utility, and a broader range of approaches should be
developed for use with any organism and cell type. This may also require identifying new cell-free environ-
ments or cell-based chassis for assembling and manipulating DNA that also have compatibility with genome
packaging and delivery systems into host organisms. Similarly to DNA assembly, delivery protocols and
their associated information regarding number of biological and technical replicate experiments, methods,
measurements, and so on, should be available in a machine-readable format. This should include information
regarding the host cell, such as its genotype, which is often not fully verified. It is unclear the extent to
which the background cellular context in which the assembled DNA is inserted affects its expression and the
ultimate phenotype of that cell.
The adoption of best practices from industrial biomanufacturing settings could provide a path forward
toward integrating appropriate measurements, process controls, and information handling for large collabo-
rations involved in engineering entire genomes. Appropriate implementation of laboratory information man-
agement systems (LIMS) into research settings could go a long way toward organizing, archiving, tracking,
and sharing information within and across the individual laboratories of a larger collaboration. Advancing
the use of automation to support the build step of the genome engineering workflow requires evaluation of
which steps may reduce costs and speed results, the availability of automated methods, ways to effectively
share those methods and adapt them across platforms and manufacturers, and straightforward ways to in-
tegrate automated steps into a larger automated workflow, as well as integrate that workflow with machine
learning. Issues concerning best-practices for cybersecurity, cyberbiosecurity, and biosecurity should also be
considered and implemented. Much the same arguments apply for the testing discussed in the next section.
3.3 Testing the function of engineered genomes
Once the final DNA constructs have been integrated to produce an engineered genome in the desired bio-
logical context, both the sequence and expression of that genome should be verified to test for the intended
phenotype. Collaborating organizations should agree on specific measurements, along with control and cali-
bration measurements, to ensure that results can be compared and used across the participant laboratories
towards achieving the final goal. The challenges of sequence verification of the engineered genome will be
similar to those described above for intermediate DNA constructs during the build process. In addition, to
assess strain fitness and other phenotypic information, any number of omics and phenotypic measurements
could be made, and measurements that return meaningful information to inform and advance the overall
workflow should be prioritized. It will be necessary to decide at which scales of biological organization,
such as single cell or population, and time, from milliseconds to days or years, the expression of the final
DNA construct should be assayed to ensure the desired phenotype for the intended purpose. Increasingly,
time-dependent attributes of cell processes and phenotype, as related to both gene expression internal to the
cell and variable environmental conditions external to the cell, are expected to impact engineering decisions,
including at the gigabase scale.
Details of particular assays are beyond the scope of this discussion, but it will likely be useful to de-
velop standards and measurement assurance targeted for testing engineered genomes, for example, to help
identify predictive relationships between genotype and phenotype or determine contributions of biological
stochasticity and measurement uncertainty to overall variability in a measured trait. Standard protocols,
reference cell lines, and the use of experimental design are examples of tools available to increase the rigor
and confidence in conclusions drawn from testing. The development of methods for absolute quantitation
would complement common relative measurements and facilitate calibration for comparability across mea-
surement techniques and measurands along the central dogma. Calibration of biological assays will also aid
in comparing results within a single laboratory over time and across different laboratories. Recent studies,
for example, for fluorescence [62, 63], absorbance [64], and RNAseq [65] measurements, demonstrate the
possibility of realizing scalable and cost-effective comparability in biological measurements. Best practices
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from biomanufacturing may be of use in informing all of these decisions.
DNA constructs are often evaluated for their associated growth phenotypes to determine the nature and
extent of unexpected consequences for cell function and fitness due to the revised genome sequence. This
is complicated by the need for accepted definitions of fitness, along with methods to measure and quantify
fitness. Often, determining fitness effects also involve measurements of metabolic burden. Guidance on
how to choose the best measure of fitness for a specific purpose or to speed the workflow would be helpful.
Engineered cell lines should also be evaluated for robustness to changes in the environmental context the
cells are likely to experience during typical use in the intended application, as we as stability over relevant
timescales to evolution or adaptation.
For a large collaboration, it will also be critical to establish shared representations and practices for
metadata, process controls, and calibration. Both the target fitness specifications and the protocols to
evaluate them will need to be described in sufficient detail to enable automation-assisted integration and
comparison of data, metadata, process controls, and calibration across laboratories. These practices will help
to ensure that testing includes measurements compatible with learning through modeling and simulation.
Although some measurements will serve both test and learn portions of the engineering workflow, such as
high-throughput metabolomics, some are likely to be different for testing the assembled DNA function and
representing that function in a model. In general, however, we expect that it will be valuable to have sufficient
metadata to track the data, conditions, and samples all the way back to the designs, in a machine-readable
manner to allow operations at scale. Appropriate LIMS tooling and curation assistance software (e.g., [66])
will be vital for enabling such metadata to be created consistently, correctly, and in a timely fashion, by
limiting the required input from human investigators.
3.4 Learning systematically from test results
Given our current limited knowledge of biology and current limited capabilities to design biology, learning
the functions that genomes encode and learning how to design genomes will be critical to gigabase-scale
genome engineering. This includes learning to predict the behavior of synthetic genomes, such as emergent
interactions between new metabolic byproducts and existing machinery; learning fundamental biology, such
as the functions of small non-coding RNA; learning design heuristics, such as preferentially using parts that
only have one function; and learning better methods and processes, such as how to share information among
teams of engineers. Developing the capabilities to predict and design the expression of genomes will likely
become increasingly essential as our capability to construct synthetic organisms matures.
Design-build-test-learn workflows are an effective way to learn fundamental biology, design principles,
and improved processes. The ideal workflow starts by using a predictive computational model, such as
a whole-cell model [48] or a whole-organism model [67], to design a genome; proceeds by constructing,
booting up, and testing this genome; and concludes by systematically learning from behavioral failures of
the genome by using the data generated from testing the genome to improve the model, our biological
knowledge, and the methods used to design, construct, and boot up the genome. One way to systematically
learn better models is to identify the minimum set of changes that must be made to the model to align its
predictions with observed behaviors of the synthetic genome. To realize these models, we should develop new
experimental methods for better characterizing the relationship between genotype and phenotype, new tools
discovering and aggregating the data needed for modeling (building on foundations such as the workflow
model introduced in SBOL 2.2 [45], and ontology resources such as OBO [68] and the Experimental Factor
Ontology [69]), new formalisms for modeling and simulating the combinatorial complexity of biology and the
multiple scales between genomes and organismal behavior, new methods for high-performance simulation
of large models, new tools verifying models, new frameworks for collaboratively building models, and new
representations for the semantic meaning and provenance of models [70, 71]. To automatically learn these
models from test data, we should develop new repositories of models of individual biological parts that can
be composed into models [72]; new methods for generating variants of models that explain new observations
by incorporating models of additional parts, alternative kinetic laws, or alternative parameter values; and
develop new model selection techniques for non-linear multiscale models [73].
Until we have comprehensive predictive models, engineers will likely rely on ad hoc combinations of
predictive models of parts of organisms, data-driven models, and heuristic design rules. BioModels [74], the
NeuroML database [75], Open Source Brain [76], and the Physiome Model Repository [77] already contain
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hundreds of models of parts of organisms that can be used to help design organisms. For example, metabolic
engineers often use constraint-based models to design microbial factories [78]. Numerous data-driven models
of parts of organisms can also already be used to help design synthetic organisms. For example, PSORTb
[79] can help bioengineers design signal sequences to traffic proteins to specific compartments. Several design
heuristics are also already commonly used. For example, bioengineers often optimize the GC content of parts
to minimize their metabolic load on their host [80].
To close the design-build-test-learn cycle, the community should describe these models and heuristics
with standard formats and share these models through public repositories. CellML [81], NeuroML [82], and
Systems Biology Markup Language [83] (SBML) formats can already be used to describe several types of
biochemical and physiological models, and the BioModels, NeuroML, Open Source Brain, and Physiome
repositories can already be used to share models. Similarly, Docker containers and the DockerHub repos-
itory [84] can already be used to share data-driven models. New formats for describing multiscale models
should be developed to help bioengineers use these models to design genomes. In particular, these formats
should support more comprehensive and more detailed models. In addition, these formats should facilitate
collaboration by concretely capturing the semantic meaning of each model component and capturing the
provenance of each model element, including the data sources, assumptions, and design decisions that moti-
vated each element. Finally, to help bioengineers reliably design genomes, these formats should also capture
the predictive performance of models, including the behaviors, biological mechanisms, and environments
which they can and cannot capture.
3.5 Coordinating complex workflows
Engineering gigabase genomes will require coordinating numerous heterogeneous tasks into clear, cohesive,
reproducible workflows [85, 86]. Several technologies have already been developed to coordinate experimen-
tal protocols, computational workflows, and other complex tasks. Laboratory automation systems enable
investigators to design and execute complex experimental protocols that involve numerous individual tasks,
reagents, equipment, and personnel [87]. To execute protocols more reproducibly than possible with manual
approaches, these systems capture the details of each task, such as the amount of each reagent, the order
of tasks, and the results of each protocol. These systems can also be integrated with LIMS [88] to help
track workflows and reagent stocks. Individual tasks could be described with languages such as Autopro-
tocol [89]. Although lab automation has not yet been widely adopted, some researchers are already using
lab automation systems, such as Aquarium [90] and Antha [91], to engineer yeast [92]. As these systems
improve and as their interfaces are standardized and integrated, the community should adopt these tools
for specifying build and test protocols. This would help large numbers of researchers execute standardized
protocols collaboratively.
On the informational side, computational workflow engines aim to enable the clear specification and
reproducible execution of complex computational workflows that involve multiple steps and require multiple
software programs and computing environments. Like lab automation systems, workflow engines aim to
capture the details of each task, the relationships among the tasks, and the dependencies of the tasks so
that workflows can be shared among investigators and reproducibly executed. Several workflow engines
such as Cromwell [93], Galaxy [94], NextFlow [95], and Toil [96] have been developed for genomics. In
addition, the Common Workflow Language [97] (CWL) enables workflows to be exchanged among several
of the most popular engines. Furthermore, the Dockstore [98] and MyExperiment [99] repositories enable
researchers to publish workflows. These tools should be adapted for gigabase engineering workflows. To make
genome engineering workflows easy to understand, we recommend that the community develop a graphical
tool for designing genome engineering workflows and an ontology for annotating the semantic meaning of
workflow tasks. To make genome engineering workflows easy to reproduce and reuse, we recommend that the
community include CWL files in COMBINE archives [100], develop REST or other programmatic interfaces
for all of the databases involved in genome engineering workflows, containerize [101] all of the computational
tools needed for genome engineering, and deposit these containers to a registry such as DockerHub [84].
Issue tracking systems, such as GitHub issues [102], can help teams coordinate the execution of complex
tasks which are difficult to describe and automate. For example, software development teams frequently use
issue tracking systems to coordinate the development of features of software. Issue tracking systems could
be readily adapted to coordinate complex tasks involved in designing genomes and learning from tests of
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genome designs that require expert analysis. Furthermore, the PROV ontology [103] could be adopted to
capture the provenance of these tasks, and to link information throughout the design-build-test-learn cycles,
as is now possible in SBOL [45].
3.6 Sharing data through common repositories
Once links are established across different portions of a workflow, unified access to information in databases
for various institutions and stages of the workflow can be accomplished using standard federation methods
and any of the various mature open tools for database management systems (DBMS).
To support collaborative sharing, genome-engineering consortia should adopt principles of FAIR (find-
able, accessible, interoperable, reproducible) data management. FAIR principles put specific emphasis on
enhancing the ability of machines to automatically find and use the data, in addition to supporting its reuse
by individual people. Some software supporting such principles for biological data sharing already exists,
such as FAIRDOMHub [104] and EDD [105], and may be adopted for this purpose.
Ultimately, the community should incorporate every aspect of the design-build-test-learn cycle into in-
tegrated, reproducible workflows. Such integrated workflows would help teams scale to gigabase genomes,
develop extensible workflows that can be adapted for similar engineering projects, and conduct genome en-
gineering transparently and reproducibly. Achieving this will require integrating lab automation systems
for systematically executing build and test tasks, workflow engines for systematically executing design and
learn tasks, and potentially issue tracking systems for managing more sophisticated tasks that require expert
input.
3.7 Laws and Contracts
Few resources are available that can be adopted for coordinating the legal and contractual interactions of
a large-scale genome-engineering project. However, some precedents could serve as the foundation for such
resources. In the realm of copyright law, the Open Source Initiative (OSI) and other software organizations
have systematized licensing to provide compatible families of licenses, and these are used widely to promote
collaboration and composability of software. These licences can be classified into four tiers: public domain,
permissive (e.g., BSD), copy-left (e.g., GPL) and proprietary. Similarly, the Creative Commons family of
licenses provide a simple framework for media and other content sharing that has been widely adopted and
is commonly incorporated into tooling. With just a single badge in such an established system of licensing, a
user or a machine can tell quickly if an object can be reused, if its reuse is prohibited, or if more complicated
negotiation or determination is required.
For dealing with physical biological materials, the first standardized materials transfer agreement was
the NIH’s Uniform Biological Materials Transfer Agreement (UBMTA), released in 1995. The Addgene
public DNA repository uses this agreement, which is widely supported by universities and enables many legal
transactions to be automated, although not for commercial uses. Broader and more compatible MTA systems
have been developed by the Science Commons project [106], and more recently by the OpenMTA [107]. No
publicly available system yet supports automation for management of protections for proprietary genetic
materials and reagents, however, and there are also significant considerations to be managed regarding
compliance with local regulatory and legal systems, particularly when materials cross international borders.
Developing a machine-compatible system of protections for scientific data and materials would enable
transfers with automated systems and reduce institutional friction. In order for such a system to work,
the genome-engineering community should define tiered levels of IP protections that are simultaneously
intelligible for the common user, legal experts, and computer systems. Enabling effective use of such systems
with automation-assisted workflows will also require recording provenance information about which inputs
are involved in the production of results, using mechanisms such as the PROV ontology [103]. Finally, large-
scale data sharing will also need to assist researchers and engineers in managing the level of exposure of
information, whether due to issues of privacy, safety, publication priority, or other similar concerns. Again,
no current systems exist, but a basis for developing them may be found in the cross-domain information
sharing protocols that have been developed in other domains [108, 109].
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4 Recommendations and Outlook
As discussed above, scaling up to gigabase genomes presents a wide range of immediate and long-term
challenges (Table 1). These cluster into four general areas, each with a different set of needs and paths for
development:
• Representing and exchanging designs, plans, data, metadata, and knowledge: Managing
information for gigabase genomic design requires addressing many challenges regarding scale, repre-
sentation, and standards. Relatively mature technologies exist to address most individual needs, as
well as to assist with the integration of workflows. The practical implementation of effective workflows
will require significant investment in building infrastructure and tools that adopt these technologies,
including domain-specific extensions and refinements.
• Sharing and integrating data quality and experimental measurements: Sharing and inte-
grating information arising from measurements of biological material poses significant challenges. It
remains unclear what information would be advantageous to share, given the difficulty of obtaining
and interpreting measurements of biological systems and the expense and unfavorable scaling of data
curation. However, effective integration depends on associating measurement data with well-curated
knowledge and metadata in compatible representations. A number of potential solutions exist for
each of these, but significant investment will be needed to investigate how the state of the art can be
extended to satisfactorily address these needs.
• Integration of modeling and design at the gigabase genomic scale: Considerable challenges
surround efforts to develop a deeper understanding of the relationship between genotype and phenotype,
regarding both the interpretation of experimental data and the application of that data to create
and validate models, which may be applied in computer-assisted design. Long-term investment in
fundamental research is needed, and the suite of biological systems of varying complexity, from cell-
free systems to minimal and synthetic cells to natural living systems, may offer suitable experimental
platforms to match genes with specific functions.
• Technical support for Ethical, Legal, and Societal Implications (ELSI) and Intellectual
Property (IP) at scale: At the gigabase scale, computer-assisted workflows will be necessary to
manage contracts, intellectual property, materials transfer, and other legal and societal interactions.
Such workflows will need to be developed by interdisciplinary teams involving experts in law, ELSI
issues, software engineering, and knowledge representation. Moreover, it will be critical to address
these issues early.
In short, engineering gigabase-scale genomes presents significant challenges that will require coordinated
investment to overcome. Because many other areas of bioscience face similar challenges, solutions to these
challenges will likely also benefit the broader bioscience community.
Importantly, the challenges of scale, integration, and lack of knowledge faced in genomic engineering are
not fundamentally different in nature than those that have been overcome previously in other engineering
ventures, such as aerospace engineering and microchip design, which required organizing humans and sharing
information across many institutions over time. Thus, we expect to be able to adapt solutions from these
other fields for genome engineering.
Investment in capabilities for genomic engineering workflows is critical to move from a world in which
genome engineering is a heroic effort to one in which genome engineering is routine, safe, and reliable.
Investment in workflows for genomic engineering will support and enable a vast number of projects, including
many not yet conceived, as was the case for reading the human genome. As workflow technologies improve,
we anticipate that the trends of Figure 1B will eventually reverse, enabling high-fidelity whole-genome
engineering at a modest cost.
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